MAP plus maintenance pegylated interferon α-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 “good response” randomization.
Stefan S. Bielack
Consultant or Advisory Role - Bayer; Merck; Takeda
Honoraria - Takeda
Sigbjorn Smeland
No relevant relationships to disclose
Jeremy Whelan
No relevant relationships to disclose
Neyssa Marina
No relevant relationships to disclose
Jane Hook
No relevant relationships to disclose
Gordana Jovic
No relevant relationships to disclose
Mark D. Krailo
No relevant relationships to disclose
Trude Butterfass-Bahloul
No relevant relationships to disclose
Thomas Kühne
No relevant relationships to disclose
Mikael Eriksson
No relevant relationships to disclose
Lisa A. Teot
No relevant relationships to disclose
Hans Gelderblom
No relevant relationships to disclose
Leo Kager
No relevant relationships to disclose
Kirsten Sundby Hall
No relevant relationships to disclose
Richard Greg Gorlick
No relevant relationships to disclose
R. Lor Randall
No relevant relationships to disclose
Pancras C. W. Hogendoorn
No relevant relationships to disclose
Gabriele Calaminus
No relevant relationships to disclose
Matthew Robert Sydes
No relevant relationships to disclose
Mark L. Bernstein
No relevant relationships to disclose